Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 co-activation.
Shah V, Giotopoulos G, Osaki H, Meyerhöfer M, Meduri E, Gallego-Crespo A, Behrendt MA, Saura-Pañella M, Tarkar A, Schubert B, Yun H, Horton SJ, Agrawal-Singh S, Hähnel PS, Basheer F, Lugo D, Eleftheriadou I, Barbash O, Dhar A, Kühn M, Guezguez B, Theobald M, Kindler T, Gallipoli P, Yeh PS-H, Dawson MA, Prinjha RK, Huntly BJ and Sasca D
Blood, American Society of Hematology 
09-12-2024

A CADASIL NOTCH3 mutation leads to clonal hematopoiesis and expansion of Dnmt3a-R878H hematopoietic clones
Sánchez-Lanzas R, Barclay J, Hardas A, Kalampalika F, Jiménez-Pompa A, Gallipoli P and Ganuza M
Leukemia, Springer Nature, 1-13.  
13-11-2024

Specific Bone Marrow Niche Components Determine Degree of Protection from Gilteritinib Induced Differentiation Response in FLT3-ITD AML
James SC, Atkinson S, Burt R, Lo Celso C and Gallipoli P
Blood, American Society of Hematology vol. 144 (Supplement 1), 4152-4152.  
05-11-2024

Acute Resistance to BET Inhibitors Remodels Compensatory Transcriptional Programs Via p300 Co-Activation
Shah V, Giotopoulos G, Osaki H, Meyerhöfer M, Meduri E, Gallego-Crespo A, Behrendt MA, Saura-Pañella M, Schubert B, Yun H, Horton SJ, Singh SA, Hähnel PS, Basheer F, Lugo D, Kühn M, Guezguez B, Theobald M, Kindler T, Gallipoli P, Yeh P, Dawson MA, Prinjha R, Huntly BJP and Sasca D
Blood, American Society of Hematology vol. 144 (Supplement 1) 
05-11-2024

Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy
Othman J, Hwang A, Brodermann M, Abdallah I, McCloskey K, Gallipoli P, Clarke G, Dang R, Vidler J, Krishnamurthy P, Basheer F, Latif A-L, Palanicawandar R, Taylor T, Khan A, Campbell V, Hogan F, Kanellopoulos A, Fleming K, Collins A, Dalley C, Loke J, Marshall S, Taussig D, Munisamy S, Loizou E, Yassin H, Dennis M, Zhao R and Belsham E
Blood Advances, American Society of Hematology vol. 8 (21), 5590-5597.  
25-10-2024

Phosphoproteomics predict response to midostaurin plus chemotherapy in independent cohorts of FLT3-mutated acute myeloid leukaemia
Borek WE, Nobre L, Pedicona SF, Campbell AE, Christopher JA, Nawaz N, Perkins DN, Moreno-Cardoso P, Kelsall J, Ferguson HR, Patel B, Gallipoli P, Arruda A, Ambinder AJ, Thompson A, Williamson A, Ghiaur G, Minden MD, Gribben JG, Britton DJ, Cutillas PR and Dokal AD
Ebiomedicine, Elsevier vol. 108 
17-09-2024

Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy
Innes AJ, Hayden C, Orovboni V, Claudiani S, Fernando F, Khan A, Rees D, Byrne J, Gallipoli P, Francis S, Copland M, Horne G, Raghavan M, Arnold C, Collins A, Cranfield T, Cunningham N, Danga A, Forsyth P, Frewin R, Garland P, Hannah G, Avenoso D, Hassan S, Huntly BJP, Husain J, Makkuni S, Rothwell K, Khorashad J and Apperley JF
Leukemia, Springer Nature vol. 38 (11), 2443-2455.  
17-09-2024

Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS
Othman J, Lam HPJ, Leong S, Basheer F, Abdallah I, Fleming K, Mehta P, Yassin H, Laurie J, Austin M, Gallipoli P, Taylor T, Dennis M, Elliot J, Clarke G, Dang R, Vidler J, Krishnamurthy P, Latif A-L, Kalkur P, Shahidianakbar M, Campbell V, Mannari D, Sutherland E, Wickramaratne T, Collins A, Zhao R, Mak H, Belsham E and Banerjee S
Blood Neoplasia, Elsevier vol. 1 (3) 
01-09-2024

Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation
Dembitz V, Lawson H, Burt R, Natani S, Philippe C, James SC, Atkinson S, Durko J, Wang LM, Campos J, Magee AMS, Woodley K, Austin MJ, Rio-Machin A, Casado P, Bewicke-Copley F, Rodriguez Blanco G, Pereira-Martins D, Oudejans L, Boet E, von Kriegsheim A, Schwaller J, Finch AJ, Patel B, Sarry J-E, Tamburini J, Schuringa JJ, Hazlehurst L, Copland III JA and Yuneva M
Leukemia, Springer Nature vol. 38 (11), 2395-2409.  
26-08-2024

Multi-drug algorithm to accurately predict best first-line treatments in newly-diagnosed acute myeloid leukemia (AML).
Rodriguez Cutillas P, Borek WE, Christopher JA, Nobre LV, Campbell A, Kelsall J, Pedicona F, Nawaz N, Perkins DN, Cardoso PM, Arruda A, Ambinder AJ, Dutta S, Gallipoli P, Sill H, Ghiaur G, Minden MD, Williamson A, Gribben JG and Dokal AD
Journal of Clinical Oncology, American Society of Clinical Oncology (Asco) vol. 42 (16_suppl), 6525-6525.  
29-05-2024

Expectations and outcomes of varying treatment strategies for CML presenting during pregnancy
Robertson HF, Milojkovic D, Butt N, Byrne J, Claudiani S, Copland M, Gallipoli P, Innes AJ, Knight K, Mahdi AJ, Parker J, Virchis A and Apperley JF
British Journal of Haematology, Wiley vol. 205 (3), 947-955.  
02-05-2024

The selective prolyl hydroxylase inhibitor IOX5 stabilizes HIF-1α and compromises development and progression of acute myeloid leukemia
Lawson H, Holt-Martyn JP, Dembitz V, Kabayama Y, Wang LM, Bellani A, Atwal S, Saffoon N, Durko J, van de Lagemaat LN, De Pace AL, Tumber A, Corner T, Salah E, Arndt C, Brewitz L, Bowen M, Dubusse L, George D, Allen L, Guitart AV, Fung TK, So CWE, Schwaller J, Gallipoli P, O’Carroll D, Schofield CJ and Kranc KR
Nature Cancer, Springer Nature vol. 5 (6), 916-937.  
18-04-2024

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy
Othman J, Tiong IS, O'Nions J, Dennis M, Mokretar K, Ivey A, Austin M, Latif A-L, Amer M, Chan WY, Crawley C, Crolla F, Cross J, Dang R, Elliot J, Fong CY, Galli S, Gallipoli P, Hogan F, Kalkur P, Khan A, Krishnamurthy P, Laurie J, Loo S, Marshall S, Mehta P, Murthy V, Nagumantry S, Pillai S and Potter N
Blood, American Society of Hematology vol. 143 (4), 336-341.  
25-01-2024

Immunodeficient NBSGW mouse strain allows chemotherapy modeling in AML patient‐derived xenografts
Dembitz V, Durko J, Campos J, James SC, Lawson H, Kranc KR and Gallipoli P
Hemasphere, Wiley vol. 8 (1) 
01-01-2024

Real-World Effectiveness of Asciminib in Patients with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: A Global Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)
Milojkovic D, Blijlevens N, Kwong Y-L, Zaidi U, Castagnetti F, Gallipoli P, Miggiano MC, Westerweel PE, Chen M, Hernandez MCG, Kell WJ, Vachhani P, Agarwal N, Colasante A, Meka S, Smyth A, Ferreira G and Janssen JJWM
Blood, American Society of Hematology vol. 142 (Supplement 1) 
02-11-2023

S124: PHOSPHOPROTEOMICS ACCURATELY PREDICTS RESPONSES TO MIDOSTAURIN PLUS CHEMOTHERAPY IN TWO INDEPENDENT COHORTS OF FLT3 MUTANT‐POSITIVE ACUTE MYELOID LEUKAEMIA
Dokal A, Borek WE, Nobre L, Pedicona SF, Wrench B, Gallipoli P, Arruda A, Campbell AE, Nawaz N, Ferguson HR, Perkins DN, Moreno‐Cardoso P, Thompson A, Williamson AJK, Minden MD, Gribben JG, Britton DJ and Cutillas PR
Hemasphere, Wiley vol. 7 (Suppl) 
01-08-2023

O20 TARGETING THE DEFECTIVE COA PATHWAY TO IMPROVE ERYTHROPOIESIS IN SF3B1-MUTANT MDS-RS PATIENTS
Philippe C, Mian S, Maniati E, Protopapa P, Bergot T, Piganeau M, Nemkov T, Di Bella D, Morales V, Finch A, D’Alessandro A, Bianchi K, Wang J, Gallipoli P, Kordasti S, Kubasch AS, Cross M, Platzbecker U, Wiseman D, Bonnet D, Bernard D, Gribben J and Rouault-Pierre K
Leukemia Research, Elsevier vol. 128 
01-05-2023

Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death
Woodley K, Dillingh LS, Giotopoulos G, Madrigal P, Rattigan KM, Philippe C, Dembitz V, Magee AMS, Asby R, van de Lagemaat LN, Mapperley C, James SC, Prehn JHM, Tzelepis K, Rouault-Pierre K, Vassiliou GS, Kranc KR, Helgason GV, Huntly BJP and Gallipoli P
Nature Communications, Springer Nature vol. 14 (1) 
14-04-2023

The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia
Fernando F, Innes AJ, Claudiani S, Pryce A, Hayden C, Byrne J, Gallipoli P, Copland M, Apperley JF and Milojkovic D
Bone Marrow Transplantation, Springer Nature vol. 58 (7), 826-828.  
04-04-2023

C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia
Sabatier M, Birsen R, Lauture L, Mouche S, Angelino P, Dehairs J, Goupille L, Boussaid I, Heiblig M, Boet E, Sahal A, Saland E, Santos JC, Armengol M, Fernández-Serrano M, Farge T, Cognet G, Simonetta F, Pignon C, Graffeuil A, Mazzotti C, Avet-Loiseau H, Delos O, Bertrand-Michel J, Chedru A, Dembitz V, Gallipoli P, Anstee NS, Loo S and Wei AH
Cancer Discovery, American Association For Cancer Research (Aacr) vol. 13 (7), 1720-1747.  
03-04-2023

Vitamin B5 and succinyl-CoA improve ineffective erythropoiesis in SF3B1-mutated myelodysplasia
Mian SA, Philippe C, Maniati E, Protopapa P, Bergot T, Piganeau M, Nemkov T, Di Bella D, Morales V, Finch AJ, D’Alessandro A, Bianchi K, Wang J, Gallipoli P, Kordasti S, Kubasch AS, Cross M, Platzbecker U, Wiseman DH, Bonnet D, Bernard DG, Gribben JG and Rouault-Pierre K
Science Translational Medicine, American Association For The Advancement of Science (Aaas) vol. 15 (685), eabn5135-eabn5135.  
01-03-2023

Targeting HIF-Hydroxylases Compromises Disease Initiation and Propagation, and Synergises with Current Therapies to Eliminate Cancer Stem Cells in AML
Lawson H, Holt-Martyn J, Dembitz V, Durko J, Kabayama Y, Wang L, Van De Lagemaat L, Dubusse L, Alunno L, Guitart A, Schwaller J, Gallipoli P, O'Carroll D, Schofield C and Kranc K
Blood, American Society of Hematology vol. 140 (Supplement 1), 8731-8732.  
15-11-2022

Real-World Experience of Asciminib: Factors Associated with Response
Innes AJ, Hayden C, Orovboni V, Rees D, Claudiani S, Fernando F, Khan A, Byrne J, Gallipoli P, Francis S, Copland M, Horne G, Raghavan M, Arnold C, Collins A, Cranfield T, Cunningham N, Danga A, Forsyth P, Frewin R, Garland P, Hannah G, Hassan S, Huntly BJP, Husain J, Makkuni S, Rothwell K, Foroni L, Apperley JF and Milojkovic D
Blood, American Society of Hematology vol. 140 (Supplement 1), 6796-6797.  
15-11-2022

Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy
Othman J, Tiong IS, Mokretar K, Ivey A, Austin MJ, Latif A-L, Crawley C, Amer M, Crolla F, Cross JW, Dang R, Fong CY, Galli S, Gallipoli P, Hogan FL, Kalkur P, Khan A, Krishnamurthy P, Laurie J, Marshall SR, Murthy V, Nagumantry SK, Pillai S, Potter N, Taylor T, Zhao R, Wei AH and Dillon R
Blood, American Society of Hematology vol. 140 (Supplement 1), 2033-2035.  
15-11-2022

AML gets upSET when its dietary needs are unMet
Gallipoli P
Blood, American Society of Hematology vol. 140 (19), 2003-2004.  
10-11-2022

A phase I/II open-label study of molibresib for the treatment of relapsed/refractory hematologic malignancies
Dawson MA, Borthakur G, Huntly B, Karadimitris A, Alegre A, Chaidos A, Vogl DT, Pollyea DA, Davies FE, Morgan GJ, Glass J, Kamdar M, Manteca M-VM, Tovar N, Yeh P, Delgado RG, Basheer F, Marando L, Gallipoli P, Wyce A, Krishnatry AS, Barbash O, Bakirtzi E, Ferron-Brady G, Karpinich NO, McCabe MT, Foley SW, Horner T, Dhar A and Kremer BE
Clinical Cancer Research, American Association For Cancer Research (Aacr) vol. 29 (4), 711-722.  
09-11-2022

P706: ASCIMINIB USE IN CML: THE UK EXPERIENCE
Innes A, Orovboni V, Claudiani S, Fernando F, Khan A, Byrne J, Gallipoli P, Copland M, Horne G, Arnold C, Collins A, Cunningham N, Danga A, Frewin R, Garland P, Hannah G, Hassan S, Makkuni S, Rothwell K, Foroni L, Hayden C, Apperley J and Milojkovic D
Hemasphere, Wiley vol. 6, 601-602.  
01-06-2022

The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia
Gallipoli P, Clark RE, Byrne J, Apperley JF, Milojkovic D, Foroni L, Goldman JM and O’Brien S
British Journal of Haematology, Wiley vol. 196 (6), e55-e57.  
06-01-2022

Vitamin B5 and Succinyl-CoA Improve Ineffective Erythropoiesis in SF3B1 Mutated Myelodysplasia
Mian S, Philippe C, Maniati E, Bergot T, Piganeau M, Di Bella D, Morales V, Finch A, Bianchi K, Wang J, Gallipoli P, Platzbecker U, Wiseman DH, Bonnet D, Bernard D, Gribben J and Rouault-Pierre K
Blood, American Society of Hematology vol. 138 (Supplement 1) 
05-11-2021

Gilteritinib for Relapsed Acute Myeloid Leukaemia with FLT3 Mutation during the COVID-19 Pandemic: Real World Experience from the UK National Health Service
Othman J, Afzal U, Amofa R, Austin MJ, Bashford A, Belsham E, Byrne J, Coats T, Dang R, Dennis M, Dhawan S, Elliot J, Francis S, Gallipoli P, Hodgson K, Kallmeyer C, Jain M, Katsomitrou V, Khan A, Khwaja A, Kolade S, Krishnamurthy P, Latif A, Laurie J, Lim M, Loke CT, Manson C, Marshall SR, Mobashwera B and Munisamy S
Blood, American Society of Hematology vol. 138 (Supplement 1) 
05-11-2021

Venetoclax with Azacitidine or Low Dose Cytarabine As an Alternative to Intensive Chemotherapy in Fit Adults during the COVID19 Pandemic: Real World Data from the UK National Health Service
Othman J, Amer M, Amofa R, Anderson L, Austin MJ, Bashford A, Belsham E, Boot J, Campbell VL, Coats T, Collins A, Crawley C, Crolla F, Cross JW, Dalley C, Dang R, Dennis M, Dhawan S, Elliott J, Galli S, Gallipoli P, Hodgson K, Jain M, Kalkur P, Katsomitrou V, Khan A, Khwaja A, Krishnamurthy P, Latif A and Laurie J
Blood, American Society of Hematology vol. 138 (Supplement 1) 
05-11-2021

Mutational synergy during leukemia induction remodels chromatin accessibility, histone modifications and three-dimensional DNA topology to alter gene expression
Yun H, Narayan N, Vohra S, Giotopoulos G, Mupo A, Madrigal P, Sasca D, Lara-Astiaso D, Horton SJ, Agrawal-Singh S, Meduri E, Basheer F, Marando L, Gozdecka M, Dovey OM, Castillo-Venzor A, Wang X, Gallipoli P, Müller-Tidow C, Osborne CS, Vassiliou GS and Huntly BJP
Nature Genetics, Springer Nature vol. 53 (10), 1443-1455.  
23-09-2021

The Role of Metabolism in the Development of Personalized Therapies in Acute Myeloid Leukemia
Dembitz V and Gallipoli P
Frontiers in Oncology, Frontiers vol. 11 
19-05-2021

Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome
Hughes CFM, Gallipoli P and Agarwal R
Pathology, Elsevier 
04-03-2021

Does Outcome/Survival of Patients With Myelodysplastic Syndromes Should Be Predicted by Reduced Levels of ADAMTS-13? Results From a Pilot Study
Castelli R, Bergamaschini L, Teatini T, Cilumbriello L, Schiavon R, Gallipoli P and Deliliers GL
Clinical Lymphoma Myeloma & Leukemia, Elsevier vol. 20 (8), e461-e467.  
31-01-2020

A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease
Horne GA, Stobo J, Kelly C, Mukhopadhyay A, Latif AL, Dixon-Hughes J, McMahon L, Cony-Makhoul P, Byrne J, Smith G, Koschmieder S, BrÜmmendorf TH, Schafhausen P, Gallipoli P, Thomson F, Cong W, Clark RE, Milojkovic D, Helgason GV, Foroni L, Nicolini FE, Holyoake TL and Copland M
Leukemia, Springer Nature vol. 34 (7), 1775-1786.  
10-01-2020

Cohesin-dependent regulation of gene expression during differentiation is lost in cohesin-mutated myeloid malignancies
Sasca D, Yun H, Giotopoulos G, Szybinski J, Evan T, Wilson NK, Gerstung M, Gallipoli P, Green AR, Hills R, Russell N, Osborne CS, Papaemmanuil E, Göttgens B, Campbell P and Huntly BJP
Blood, American Society of Hematology vol. 134 (24), 2195-2208.  
12-12-2019

Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)
Claudiani S, Metelli S, Kamvar R, Szydlo R, Khan A, Byrne J, Gallipoli P, Bulley SJ, Horne GA, Rothwell K, Copland M, Clark RE, Khorashad JS, Foroni L, Milojkovic D and Apperley JF
Blood, American Society of Hematology vol. 134 (Supplement_1) 
13-11-2019

Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML
Basheer F, Giotopoulos G, Meduri E, Yun H, Mazan M, Sasca D, Gallipoli P, Marando L, Gozdecka M, Asby R, Sheppard O, Dudek M, Bullinger L, Döhner H, Dillon R, Freeman S, Ottmann O, Burnett A, Russell N, Papaemmanuil E, Hills R, Campbell P, Vassiliou GS and Huntly BJP
Journal of Experimental Medicine, Rockefeller University Press vol. 216 (4), 966-981.  
19-03-2019

Histone modifiers are oxygen sensors
Gallipoli P and Huntly BJP
Science, American Association For The Advancement of Science (Aaas) vol. 363 (6432), 1148-1149.  
15-03-2019

Prognostic Models Turn the Heat(IT)up on FLT3ITD-Mutated AML
Gallipoli P and Huntly BJP
Clinical Cancer Research, American Association For Cancer Research (Aacr) vol. 25 (2), 460-462.  
15-01-2019

SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4
Tzelepis K, De Braekeleer E, Aspris D, Barbieri I, Vijayabaskar MS, Liu W-H, Gozdecka M, Metzakopian E, Toop HD, Dudek M, Robson SC, Hermida-Prado F, Yang YH, Babaei-Jadidi R, Garyfallos DA, Ponstingl H, Dias JML, Gallipoli P, Seiler M, Buonamici S, Vick B, Bannister AJ, Rad R, Prinjha RK, Marioni JC, Huntly B, Batson J, Morris JC, Pina C and Bradley A
Nature Communications, Springer Nature vol. 9 (1) 
19-12-2018

Increased risk of heparin induced thrombocytopenia and thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation
Castelli R, Gallipoli P, Schiavon R, Teatini T, Deliliers GL and Bergamaschini L
Journal of Thrombosis and Thrombolysis, Springer Nature vol. 47 (1), 155-156.  
26-11-2018

JAK of all trades: Ruxolitinib as a new therapeutic option for CML patients
Gallipoli P
Leukemia Research, Elsevier vol. 75, 71-72.  
24-10-2018

Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition
Gallipoli P, Giotopoulos G, Tzelepis K, Costa ASH, Vohra S, Medina-Perez P, Basheer F, Marando L, Di Lisio L, Dias JML, Yun H, Sasca D, Horton SJ, Vassiliou G, Frezza C and Huntly BJP
Blood, American Society of Hematology vol. 131 (15), 1639-1653.  
20-02-2018

High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation
Castelli R, Gallipoli P, Schiavon R, Teatini T, Deliliers GL and Bergamaschini L
Journal of Thrombosis and Thrombolysis, Springer Nature vol. 45 (1), 106-113.  
11-10-2017

Novel epigenetic therapies in hematological malignancies: Current status and beyond
Gallipoli P and Huntly BJP
Seminars in Cancer Biology, Elsevier vol. 51, 198-210.  
04-08-2017

CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression.
Tarafdar A, Hopcroft LE, Gallipoli P, Pellicano F, Cassels J, Hair A, Korfi K, Jørgensen HG, Vetrie D, Holyoake TL and Michie AM
Blood 
28-10-2016

A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia
Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, Mupo A, Grinkevich V, Li M, Mazan M, Gozdecka M, Ohnishi S, Cooper J, Patel M, McKerrell T, Chen B, Domingues AF, Gallipoli P, Teichmann S, Ponstingl H, McDermott U, Saez-Rodriguez J, Huntly BJP, Iorio F, Pina C, Vassiliou GS and Yusa K
Cell Reports, Elsevier vol. 17 (4), 1193-1205.  
01-10-2016

Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition.
Scott MT, Korfi K, Saffrey P, Hopcroft LE, Kinstrie R, Pellicano F, Guenther C, Gallipoli P, Cruz M, Dunn K, Jorgensen HG, Cassels JE, Hamilton A, Crossan A, Sinclair A, Holyoake TL and Vetrie D
Cancer Discovery, American Association For Cancer Research vol. 6 (11), 1248-1257.  
14-09-2016

Laboratory and clinical risk assessment to treat myelodysplatic syndromes
Gidaro A, Deliliers GL, Gallipoli P, Arquati M, Wu MA and Castelli R
Clinical Chemistry and Laboratory Medicine, De Gruyter vol. 54 (9), 1411-1426.  
14-01-2016

Salvage therapy with bortezomib and dexamethasone in elderly patients with relapsed/refractory multiple myeloma
Castelli R, Pantaleo G, Gallipoli P, Gidaro A, Arquati M, Wu MA and Deliliers GL
Anti-Cancer Drugs, Wolters Kluwer vol. 26 (10), 1078-1082.  
01-11-2015

A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression
Giotopoulos G, van der Weyden L, Osaki H, Rust AG, Gallipoli P, Meduri E, Horton SJ, Chan W-I, Foster D, Prinjha RK, Pimanda JE, Tenen DG, Vassiliou GS, Koschmieder S, Adams DJ and Huntly BJP
Journal of Experimental Medicine, Rockefeller University Press vol. 212 (10), 1551-1569.  
24-08-2015

Bayesian inference for model selection: an application to aberrant signalling pathways in chronic myeloid leukaemia
Hopcroft LEM, Calderhead B, Gallipoli P, Holyoake TL and Girolami MA
In Systems Genetics, Cambridge University Press (Cup) 161-190.  
02-07-2015

Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia
Gallipoli P, Giotopoulos G and Huntly BJP
Therapeutic Advances in Hematology, Sage Publications vol. 6 (3), 103-119.  
27-04-2015

The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia
Giotopoulos G, Chan W-I, Horton SJ, Ruau D, Gallipoli P, Fowler A, Crawley C, Papaemmanuil E, Campbell PJ, Göttgens B, Van Deursen JM, Cole PA and Huntly BJP
Oncogene, Springer Nature vol. 35 (3), 279-289.  
20-04-2015

JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo
Gallipoli P, Cook A, Rhodes S, Hopcroft L, Wheadon H, Whetton AD, Jørgensen HG, Bhatia R and Holyoake TL
Blood, American Society of Hematology vol. 124 (9), 1492-1501.  
23-06-2014

Thrombosis and Hemostatic Abnormalities in Hematological Malignancies
Colombo R, Gallipoli P and Castelli R
Clinical Lymphoma Myeloma & Leukemia, Elsevier vol. 14 (6), 441-450.  
11-06-2014

Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function
Castelli R, Deliliers GL, Colombo R, Moreo G, Gallipoli P and Pantaleo G
Annals of Hematology, Springer Nature vol. 93 (9), 1523-1529.  
08-04-2014

The Epigenetic Regulators CBP and p300 Facilitate Leukemogenesis and Represent Therapeutic Targets In Acute Myeloid Leukemia (AML)
Giotopoulos G, Chan W-I, Ruau D, Gallipoli P, Fowler A, Göttgens B, Van Deursen J, Cole P and Huntly B
Blood, American Society of Hematology vol. 122 (21) 
15-11-2013

Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation
Gallipoli P, Pellicano F, Morrison H, Laidlaw K, Allan EK, Bhatia R, Copland M, Jørgensen HG and Holyoake TL
Blood, American Society of Hematology vol. 122 (19), 3335-3339.  
16-09-2013

Safety and efficacy of pulsed imatinib with or without G‐CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow‐up
Gallipoli P, Stobo J, Heaney N, Nicolini FE, Clark R, Wilson G, Tighe J, McLintock L, Hughes T, Michor F, Paul J, Drummond M and Holyoake TL
British Journal of Haematology, Wiley vol. 163 (5), 674-676.  
19-08-2013

Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex
Chen M, Gallipoli P, DeGeer D, Sloma I, Forrest DL, Chan M, Lai D, Jorgensen H, Ringrose A, Wang HM, Lambie K, Nakamoto H, Saw KM, Turhan A, Arlinghaus R, Paul J, Stobo J, Barnett MJ, Eaves A, Eaves CJ, Holyoake TL and Jiang X
Journal of The National Cancer Institute, Oxford University Press (Oup) vol. 105 (6), 405-423.  
27-02-2013

Neutrophil‐specific granule deficiency
McIlwaine L, Parker A, Sandilands G, Gallipoli P and Leach M
British Journal of Haematology, Wiley vol. 160 (6), 735-735.  
08-01-2013

Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro
Shah M, Gallipoli P, Lyons J, Holyoake T and Jørgensen H
Blood Cells Molecules and Diseases, Elsevier vol. 48 (3), 199-201.  
09-02-2012

Hurdles Toward a Cure for CML: The CML Stem Cell
Gallipoli P, Abraham SA and Holyoake TL
Hematology/Oncology Clinics of North America, Elsevier vol. 25 (5), 951-966.  
01-10-2011

Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study
Gallipoli P, Shepherd P, Irvine D, Drummond M and Holyoake T
British Journal of Haematology, Wiley vol. 155 (1), 128-130.  
22-04-2011

Combined Targeting of BCR-ABL and JAK2 with ABL and JAK2 Inhibitors Is Effective Against CML Patients' Leukemic Stem/Progenitor Cells.
DeGeer D, Gallipoli P, Chen M, Sloma I, Jorgensen H, Forrest D, Lambie K, Nakamoto H, Saw KM, Chan M, Newmarch K, Zhou L, Turhan AG, Arlinghaus RB, Eaves AC, Eaves CJ, Holyoake TL and Jiang X
Blood, American Society of Hematology vol. 116 (21) 
19-11-2010

Targeted therapy in haematological malignancies
Hamilton A, Gallipoli P, Nicholson E and Holyoake TL
The Journal of Pathology, Wiley vol. 220 (4), 404-418.  
29-12-2009

The evolving management of a rare lymphoproliferative disorder–T‐cell prolymphocytic leukemia
Gallipoli P, Clark A and Leach M
American Journal of Hematology, Wiley vol. 84 (11), 750-753.  
27-08-2009

Multiple splenic calcifications
Fyfe AJ and Gallipoli P
British Journal of Haematology, Wiley vol. 144 (6), 808-808.  
19-02-2009

Hemophagocytosis and relapsed peripheral T‐cell lymphoma
Gallipoli P, Drummond M and Leach M
European Journal of Haematology, Wiley vol. 82 (3), 246-246.  
27-01-2009

Pseudotumour cerebri as a manageable side effect of prolonged all‐trans retinoic acid therapy in an adult patient with acute promyelocytic leukaemia
Gallipoli P and Drummond M
European Journal of Haematology, Wiley vol. 82 (3), 242-243.  
27-01-2009

Cortical blindness due to sagittal sinus thrombosis in acute lymphoblastic leukaemia
Gallipoli P, Tang A and Leach M
British Journal of Haematology, Wiley vol. 145 (3), 270-270.  
05-11-2008

Gingival infiltration in acute monoblastic leukaemia
Gallipoli P and Leach M
British Dental Journal, Springer Nature vol. 203 (9), 507-509.  
01-11-2007

Assessment of physical activity in an outpatient obesity clinic in southern Italy: Results from a standardized questionnaire
Finelli C, Gallipoli P, Celentano E, Cacace G, Saldalamacchia G, De Caprio C, Contaldo F and Pasanisi F
Nutrition Metabolism and Cardiovascular Diseases, Elsevier vol. 16 (3), 168-173.  
06-10-2005

Medical education: Britain versus Italy
Gallipoli P
The Bmj, Bmj vol. 324 (Suppl S2) 
01-02-2002

Glasgow: a very interesting place
Gallipoli P
The Bmj, Bmj vol. 324 (Suppl S2) 
01-02-2002

Functional expression and CNS distribution of a β-alanine-sensitive neuronal GABA transporter
Clark JA, Deutch AY, Gallipoli PZ and Amara SG
Neuron, Elsevier vol. 9 (2), 337-348.  
01-08-1992